, Volume 20, Issue 2, pp S95–S99 | Cite as

Granulocyte-macrophage colony-stimulating factor (GM-CSF): what role in bone marrow transplantation?

  • M. W. Schuster


Infection during the period of bone marrow aplasia remains one of the major risks associated with high-dose chemotherapy and transplantation. Over the past several years, a number of investigators in Europe and North America have evaluated the use of GM-CSF in the setting of autologous bone marrow transplantation. These studies have almost all shown a hastening of myeloid engraftment. This, for the most part, has led to fewer serious infections and a decreased hospital stay for the GM-CSF treated patients. An overall survival advantage has not been noted. There has also not been any consistent multi-lineage effect. Future trials with combinations of sequentially used cytokines may lead to more rapid recovery of red blood cells and platelets in addition to granulocytes.

Welche Bedeutung hat der Granulozyten-Makrophagen-stimulierende Faktor (GM-CSF) bei der Knochenmarktransplantation?


Infektionen in der Phase der Knochenmarkaplasie nach Hochdosis-Chemotherapie und Knochenmarktransplantation stellen nach wie vor eine große Gefahr dar. Der Einsatz von GM-CSF bei autologer Knochenmarktransplantation wurde in den vergangenen Jahren von mehreren Forschungsgruppen in Europa und Nordamerika erprobt. In fast allen Studien wurde eine Beschleunigung des Knochenmark-Engraftment beobachtet. Bei den meisten mit GM-CSF behandelten Patienten war dies mit einer Reduktion schwerer Infektionen und Verkürzung des Krankenhausaufenthaltes verbunden. Doch war insgesamt keine Lebensverlängerung nachzuweisen. Eine Beeinflussung multipler Zellinien konnte nicht konstant festgestellt werden. Eine raschere Erholung der Erythrozyten und Thrombozyten und nicht nur der Granulozyten wird mit der sequentiellen Anwendung kombinierter Zytokine erwartet, die in zukünftigen Studien geprüft werden sollen.


  1. 1.
    Armitage, J. O. Bone marrow transplantation in the treatment of patients with lymphoma. Blood 73 (1989) 1749–1758.Google Scholar
  2. 2.
    Sallan, S. E., Niemeyer, C. M., Billett, A. L., Lipton, J. M., Tarbell, N. J., Gelber, R. D., Murray, L., Pittinger T. P., Wolfe, L. C., Bast, R. C., Ritz, J. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J. Clin. Oncol. 7 (1989) 1594–1601.Google Scholar
  3. 3.
    Peters, W. P., Shpall, E. J., Jones, R. B., Olsen, G. A., Bast, R. C., Gockerman, J. P., Moore, J. O. High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J. Clin Oncol. 6 (1988) 1368–1376.Google Scholar
  4. 4.
    Broun, E. R., Nichols, C. R., Kneebone, P., Williams, S. R., Loehrer, P. F., Einhorn, L. H., Tricot, G. J. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow transplantation. Ann. Intern. Med. 117 (1992) 124–128.Google Scholar
  5. 5.
    Nichols, L. R., Tricot, G., Williams, S. D., Van Besien, K., Loehrer, P. J., Roth, B. J., Akard, L., Hoffman, R., Goulet, R., Wolff, S. N., Giannone, L., Greer, J., Einhorn, L. H., Jansen, J. Dose-intensive chemotherapy in refractory germ cell cancer — a phase I/II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation. J. Clin Oncol. 7 (1989) 932–939.Google Scholar
  6. 6.
    Barlogie, B., Alexanian, R., Dicke, K. A., Zagers, G., Spitzer, G., Jagannath, S., Horwitz, L. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70 (1987) 869–872.Google Scholar
  7. 7.
    Parkman, R. Current states of bone marrow transplantation in pediatric oncology. Cancer 58 (Suppl. 2) 1986 569–572.Google Scholar
  8. 8.
    Phillips, G. L., Fay, J. W., Herzig, G. P., Herzig, R. H., Weiner, R. S., Wolff, S. N., Lazarus, H. M., Karanes, C., Ross, W. E., Kramer, B. S. Intensive 1, 2-bis (2-chlorethyl)-1-nitrosourea (BCNU), NSC #4366150 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study. Cancer 52 (1983) 1792–1802.Google Scholar
  9. 9.
    Rabinowe, S. N., Nemunaitis, J., Armitage, J. Nadler, L. M. The impact of myeloid growth factors on engraftment following autologus bone marrow transplantation for malignant lymphoma. Semin. Hematol. 28 1991 6–16.Google Scholar
  10. 10.
    Gasson, J. C. Molecular physiology of granulocyte-macrophage colony-stimulating factor. Blood 77 (1991) 1131–1145.Google Scholar
  11. 11.
    Ruef, C., Coleman, D. L. Granulocyte-macrophage colony stimulating factor: Pleiotropic cytokine with potential clinical usefulness. Rev. Inf. Dis. 12 (1990) 41–62.Google Scholar
  12. 12.
    Zimmerli, W., Zarth, A., Gratwohl, A., Nissen, C., Speck, G. Granulocyte-macrophage colony-stimulating factor for granulocyte defects of bone marrow transplant patients. Lanceti (1989) 494.Google Scholar
  13. 13.
    Schuster, M. W. The promise and controversy of cytokines in the treatment of myelodysplastic syndrome. In:Murphy, M. J., (ed.): Concise reviews in clinical and experimental hematology. Alpha Med Press, Dayton, Ohio 1992, pp. 83–90.Google Scholar
  14. 14.
    Guinan, E. C., Sieff, C. A., Oette, D. H., Nathan, D. G. A phase I/II trial of recombinant granulocyte-macrophage colony-stimulating factor for children with aplastic anemia. Blood 76 (1990) 1077–1082.Google Scholar
  15. 15.
    Gerhartz, H. H., Stern, A. C., Wolf-Horning, B. M.: Treatment of neutropenia in patients undergoing cancer chemotherapy. In:Scarffe, J. H., (ed.): Breakthrough in cytokine therapy: an overview of GM-CSF, London: International Congress and Symposium Series, Royal Society of Medicine Services (1991) 79–93.Google Scholar
  16. 16.
    Welte, K., Zeidler, C., Reiter, A., Müller, W., Odenwald, E., Souza, L., Riehm, H. Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congential neutropenia. Blood 75 (1990) 1056–1063.Google Scholar
  17. 17.
    Brandt, S. T., Peters, W. P., Atwater, S. K., Kurtzberg, J., Borowitz, M. J., Jones, R. B., Shpall, E. J., Bast, R. C., Gilbert, C. J., Oette, D. H. Effect of recombinant granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 318 (1988) 869–876.Google Scholar
  18. 18.
    Link, H., Seidel, J., Stoll, M., Kirchner, H., Linderkamp, C., Freund, M., Bucsky, P., Welte, K., Riehm, H., Burdach, S., Hauch, M., Koci, B., Schultz, G., Poliwoda, H. Regeneration of granulopoiesis with recombinant human granulocyte-macrophage colony-stimulating factor after bone marrow transplantation. Hematology and Blood Transfusion 33 (1990) 741–746.Google Scholar
  19. 19.
    Link, H. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) for hematological reconstitution after autologous bone marrow transplantation. In:Champlin, R. E., Gale, R. P. (eds.): New strategies in bone marrow transplantation. Wiley-Liss, New York 1991, pp. 313–335.Google Scholar
  20. 20.
    Link, H., Freund, M., Kirchner, H., Stoll, M. Schmid, H., Bucsky, P., Seidel, J., Schulz, G., Schmidt, R. E., Riehm, H., Poliwoda, H., Welte, K. Recombinant human granulocyte-macrophage colony-stimulating factor(rhGM-CSF) after bone marrow transplantation. Behring Inst. Mitt. 83 (1988) 313–319.Google Scholar
  21. 21.
    Link, H., Boogaerts, M., Carella, A., Ferrant, A., Gadner, H., Gorin, N. C., Harabacz Im Harrousseau, F., Herue, P., Kolb, H. C., Krieger, O. Labar, B., Linkesch, W., Mandelli, F., Maraninchini, D., Nicolay, U., Niederwieser, D., Reiffers, J., Rizzoli, U., Siegert, W., Slavin, S., Lernant, J. P., De Witte, T.: Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after autologus bone marrow transplantation for acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a randomized double blinded multicenter trial in Europe. Blood 76 (Suppl. 1) (1990) 152 a.Google Scholar
  22. 22.
    Blazar, B. R., Kersey, J. H., McGlave, P. B., Vallera, D. A., Lasky, L. C., Haake, R. J., Bostrom, B., Weisorf, D. R., Epstein, C., Ramsay, N. K. In vivo administration of recombinant human granulocyte-macrophage colony-stimulating factor in acute lymphoblastic leukemia patients receiving purged autografts. Blood 73 (1989) 849–857.Google Scholar
  23. 23.
    Nemunaitis, J., Singer, J. W., Buckner, C. P., Hill, R., Storb, R., Thomas, E. D., Appelbaum, F. Use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation for lymphoid malignancies. Blood 72 (1988) 834–836.Google Scholar
  24. 24.
    Devereaux, S., Linch, D. C., Gribben, J. G., McMillan, A., Patterson, K., Goldstone, A. GM-CSF accelerated neutrophil recovery after autologous bone marrow transplantation for Hodgkin's disease. Bone Marrow Transplant. 4 (1989) 49–54.Google Scholar
  25. 25.
    Fouillard, L., Gorin, N. C., Laporte, J. P. H., Douay, L., Isnard, F., Najman, A. Recombinant human granulocyte-macrophage colony-stimulating factor plus the BEAM regimen instead of autologus bone marrow transplantation. Lancet i(1989) 1460–1461.Google Scholar
  26. 26.
    Laporte, J. P. H., Fouillard, L., Douay, L., Eugene-Jochine, I., Isnard, F., Stachowiak, J., Najaman, A., Gorin, N. GM-CSF instead of autologus bone marrow transplantation after the BEAM regimen. Lancet 338 (1991) 601–602.Google Scholar
  27. 27.
    Lazarus, H., Anderson, J., Oette, O., Donovan, C., Gerson, S., Beshorner, W., Chen, M., Oken, M. Phase II ECOG trial of recombinant granulocyte-macrophage colony-stimulating factor (rhGM-CSF) after autologus bone marrow transplant (AuBMT) for relapsed non-Hodgkin's lymphoma (NHL). Proc. Am. Soc. Clin. Oncol. 9 (1990) 15 (abstract 51).Google Scholar
  28. 28.
    Linkesch, W., Kuhrer, I., Wagner, A. rHU-GM-CSF after ultra-high dose carboplatin, VP-16, cyclophosphamide with ABMT in refractory germ cell cancer. Proc. Am. Soc. Clin. Med. 9 (1990) 141 (abstract 547).Google Scholar
  29. 29.
    Gorin, N. C., Coiffer, B., Pico, J.: Granulocyte-macrophage colony-stimulating factor shortens aplasia during autologous bone marrow transplantation in non-Hodgkin's lymphoma. A randomized placebo-controlled double blind study. Blood 76 (1990) 542 a.Google Scholar
  30. 30.
    Michon, J., Bouffet, E., Bernard, J. L., Lopez, M., Philip, I., Gentet, J. C., Zucker, J. M., Philip, T. Administration of recombinant human GM-CSF (rHuGM-CSF) after autologus bone marrow transplantation (ABMT). A study of 24 stage IV neuroblastoma patients undergoing a double intensification regimen. Proc. Am. Soc. Clin. Oncol. 9 (1990) 184 (abstract 712).Google Scholar
  31. 31.
    Nemunaitis, J., Rabinowe, S. N., Singer, J. W., Bierman, P. J., Vose, J. M., Freedman, A. S., Onetto, N., Gilles, S., Oette, D., Gold, M., Buckner, C. P., Hansen, J. A., Ritz, J., Appelbaum, F. R., Armitage, J. O., Nadler, L. M. Recombinant granulocyte-macrophage colony-stimulating factor after autologus bone marrow transplantation: Pooled results from three randomized double-blind, placebo-controlled trials. N. Engl. J. Med. 324 (1991) 1773–1778.Google Scholar
  32. 32.
    Gulati, S. C., Bennett, C. L. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease. Ann. Intern. Med. 116 (1992) 117–182.Google Scholar
  33. 33.
    Peters, W. P. The effects of recombinant human colony-stimulating factors on hematopoietic reconstitution following autologous bone marrow transplantation. Semin. Hematol. 26 (1989) 18–23.Google Scholar
  34. 34.
    Aurer, I., Ribas, A., Gale, R. P. What is the role of recombinant colony-stimulating factors in bone marrow transplantation? Bone Marrow Transplant 6 (1990) 79–87.Google Scholar
  35. 35.
    Schuster, M. W., Flon, M., Sahdev, I., Godder, K., James-Herry, A., Vaughan, R. B., Abels, R.: GM-CSF and erythropoietin versus placebo in autologous bone marrow transplantation. Eur. J. Oncol. (in press).Google Scholar

Copyright information

© MMV Medizin Verlag GmbH München 1992

Authors and Affiliations

  • M. W. Schuster
    • 1
  1. 1.Don Monti Div. of Oncology and Div. of Hematology, Dept. of MedicineNorth Shore University Hospital — Cornell University Medical CollegeManhassetUSA

Personalised recommendations